Is recombinant as effective as plasma-derived clotting factor?
Both plasma-derived and recombinant clotting factor products work in the same way to replace the missing blood clotting agents in the blood and raise clotting factor levels to sufficient level to prevent or stop bleeding. Clinical trials have found both plasma-derived and recombinant clotting factor to be effective in the treatment of haemophilia. In practice some patients who have previously used plasma products may experience differences in using recombinant treatment. For example, there have been some differences reported in using recombinant factor IX. Although the recombinant factor IX product, BeneFix, has been found to work effectively in clinical trials, to achieve the same laboratory measure of factor IX after an infusion, the dose required can be higher than for plasma-derived. Individuals may, or may not, find that this is significant in terms of whether it works to treat a bleed. Some patients have required higher doses, but some have found that the treatment works for them
Related Questions
- How many haemophiliacs in the U.K. have been treated with U.K.-source plasma-derived clotting factor concentrates (CFCs) in the critical years of 1980 to 2000?
- How common are inhibitors and are there differences between haemophilia A and B?
- Is recombinant as effective as plasma-derived clotting factor?
